Mounjaro & the Brain: New Study Reveals Potential Link Between Diabetes Drug and Reduced Food Cravings
A groundbreaking new study suggests that the popular diabetes and weight loss drug tirzepatide, sold under the brand name Mounjaro, may directly impact brain activity related to food cravings. The research, published in Nature Medicine, offers a first glimpse into how these medications-including Ozempic and Wegovy-might “quieten ‘food noise'” in the brain, though scientists caution the findings are preliminary.
The investigation focused on three participants with severe obesity who had struggled with weight loss despite previous treatments, including bariatric surgery. All three continued to experience intense preoccupation with food. Researchers discovered that when participants experienced strong food cravings, a region of the brain called the nucleus accumbens-a key component of the brain’s reward system-exhibited heightened delta-theta signals.
To further explore this connection, two participants underwent deep-brain stimulation of the nucleus accumbens. Concurrently, one participant was prescribed tirzepatide for their type 2 diabetes. Brain activity was monitored in all three using implanted electrodes. Interestingly, the participant taking tirzepatide experienced a notable reduction in “severe food preoccupation” episodes within four months of starting the medication, coinciding with their brain implant surgery.
During this period, the delta-theta activity in the participant’s nucleus accumbens during cravings was indistinguishable from periods without food preoccupation-a stark contrast to the other two participants. However,this benefit proved temporary. Approximately five to seven months after the implantation surgery, the participant on tirzepatide began experiencing a resurgence of cravings and intrusive thoughts about food, despite remaining on the maximum dosage. correspondingly, the delta-theta waves in their nucleus accumbens increased again.
“Our findings raise the possibility that this delta-theta band oscillation could serve as a target engagement biomarker, but its relationship to food preoccupation warrants more controlled investigation,” the study authors conclude. This suggests that monitoring these brain signals could potentially help determine how effectively the drug is working, but further research is needed.
Mounjaro, along with Wegovy and Ozempic, operates by mimicking a natural hormone in the body, leading to reduced appetite and slower digestion. While this study represents a crucial first step in understanding the neurological effects of these drugs, researchers emphasize its limitations.the absence of a control group means that drawing definitive conclusions is challenging. Nevertheless, as one of the first in-human investigations of Mounjaro’s impact on the brain, the study opens new avenues for research.
News Report Summary:
Why: Researchers investigated how tirzepatide (Mounjaro) affects brain activity related to food cravings in individuals with severe obesity. The goal was to understand the neurological mechanisms behind the drug’s impact on appetite and food preoccupation.
Who: The study involved three participants with severe obesity who had previously undergone bariatric surgery but continued to struggle with food cravings. Researchers from Choi et al. (2025) conducted the study.
What: The study found that tirzepatide initially reduced “severe food preoccupation” in one participant, correlating with a decrease in delta-theta brain wave activity in the nucleus accumbens (the brain’s reward center). Though, this effect was temporary, with cravings and brain activity returning after five to seven months.
How did it end?:
